[
  {
    "ts": null,
    "headline": "Johnson & Johnson (JNJ)’s Pasritamig Shows Breakthrough Promise in Prostate Cancer",
    "summary": "We recently published 10 Most Undervalued Pharma Stocks To Buy Now. Johnson & Johnson stands second among the most undervalued stocks. Johnson & Johnson (NYSE:JNJ) is a global healthcare leader with a diverse portfolio across pharmaceuticals, medical devices, and consumer health. Its Innovative Medicine division focuses on treatments for complex diseases, while MedTech develops minimally […]",
    "url": "https://finnhub.io/api/news?id=86b52d248dc5a7945c09602754a297e546ab3bdf5754985a74b1ec50242ccf30",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753136789,
      "headline": "Johnson & Johnson (JNJ)’s Pasritamig Shows Breakthrough Promise in Prostate Cancer",
      "id": 136031289,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "We recently published 10 Most Undervalued Pharma Stocks To Buy Now. Johnson & Johnson stands second among the most undervalued stocks. Johnson & Johnson (NYSE:JNJ) is a global healthcare leader with a diverse portfolio across pharmaceuticals, medical devices, and consumer health. Its Innovative Medicine division focuses on treatments for complex diseases, while MedTech develops minimally […]",
      "url": "https://finnhub.io/api/news?id=86b52d248dc5a7945c09602754a297e546ab3bdf5754985a74b1ec50242ccf30"
    }
  },
  {
    "ts": null,
    "headline": "AstraZeneca announces $50 billion US manufacturing investment, matching its big pharma peers",
    "summary": "AstraZeneca announces largest ever investment in U.S. manufacturing",
    "url": "https://finnhub.io/api/news?id=655208f1672cea4d00a5215ad51b6c505853d35d1972d8711b057becac987943",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753133401,
      "headline": "AstraZeneca announces $50 billion US manufacturing investment, matching its big pharma peers",
      "id": 136031229,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "AstraZeneca announces largest ever investment in U.S. manufacturing",
      "url": "https://finnhub.io/api/news?id=655208f1672cea4d00a5215ad51b6c505853d35d1972d8711b057becac987943"
    }
  },
  {
    "ts": null,
    "headline": "Looking for Cheap Stocks? Healthcare Shares Haven’t Looked This Good in 30 Years.",
    "summary": "A Goldman ranking of S&P 500 sectors by price/earnings ratios reveals opportunities in healthcare stocks.",
    "url": "https://finnhub.io/api/news?id=cd17fd1452b4268272a9f25932e02fa3a251bf4ddd1b877b3cdb8c32293636a7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753116000,
      "headline": "Looking for Cheap Stocks? Healthcare Shares Haven’t Looked This Good in 30 Years.",
      "id": 136031230,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "A Goldman ranking of S&P 500 sectors by price/earnings ratios reveals opportunities in healthcare stocks.",
      "url": "https://finnhub.io/api/news?id=cd17fd1452b4268272a9f25932e02fa3a251bf4ddd1b877b3cdb8c32293636a7"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson (JNJ) is a Top Dividend Stock Right Now: Should You Buy?",
    "summary": "Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes? Let's find out.",
    "url": "https://finnhub.io/api/news?id=0a8d2b2d09809651f15aec6b5fab1a2db6c58eb88e7ba303d53f62d5432ebced",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753112703,
      "headline": "Johnson & Johnson (JNJ) is a Top Dividend Stock Right Now: Should You Buy?",
      "id": 136031292,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes? Let's find out.",
      "url": "https://finnhub.io/api/news?id=0a8d2b2d09809651f15aec6b5fab1a2db6c58eb88e7ba303d53f62d5432ebced"
    }
  },
  {
    "ts": null,
    "headline": "Earnings live: Verizon, Domino's kick off busy week for second quarter earnings",
    "summary": "This week, 112 S&P 500 companies report Q2 results in a busy week for corporate earnings reports.",
    "url": "https://finnhub.io/api/news?id=a2da5556a75afa19f30346c5ac82f368ab7fa38a1124bdffa9d30f3a0dc09830",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753108656,
      "headline": "Earnings live: Verizon, Domino's kick off busy week for second quarter earnings",
      "id": 136025326,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "This week, 112 S&P 500 companies report Q2 results in a busy week for corporate earnings reports.",
      "url": "https://finnhub.io/api/news?id=a2da5556a75afa19f30346c5ac82f368ab7fa38a1124bdffa9d30f3a0dc09830"
    }
  },
  {
    "ts": null,
    "headline": "VTRS Down on Late-Stage Study Failure of Eye Disease Drug",
    "summary": "VTRS slides after phase III trial failure for blepharitis drug MR-139, adding pressure to an already struggling stock.",
    "url": "https://finnhub.io/api/news?id=a239a0ac6da5909406d12895409c67c99a513b33cef1b703a2ffa5d57c16c023",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753105680,
      "headline": "VTRS Down on Late-Stage Study Failure of Eye Disease Drug",
      "id": 136025433,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "VTRS slides after phase III trial failure for blepharitis drug MR-139, adding pressure to an already struggling stock.",
      "url": "https://finnhub.io/api/news?id=a239a0ac6da5909406d12895409c67c99a513b33cef1b703a2ffa5d57c16c023"
    }
  },
  {
    "ts": null,
    "headline": "Betting Big on Cancer: 3 Oncology Stocks Set to Surge in 2025",
    "summary": "J&J, Novartis and Allogene Therapeutics are making bold oncology moves as demand surges for next-generation cancer therapies.",
    "url": "https://finnhub.io/api/news?id=b68b0e8b783d65219841418cceddcf5f3bd8e35ed1c4cc6bf5878cb8d8027ef6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753105260,
      "headline": "Betting Big on Cancer: 3 Oncology Stocks Set to Surge in 2025",
      "id": 136025389,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "J&J, Novartis and Allogene Therapeutics are making bold oncology moves as demand surges for next-generation cancer therapies.",
      "url": "https://finnhub.io/api/news?id=b68b0e8b783d65219841418cceddcf5f3bd8e35ed1c4cc6bf5878cb8d8027ef6"
    }
  },
  {
    "ts": null,
    "headline": "Should J&J Stock Be in Your Portfolio After Q2 Beat & Guidance Raise?",
    "summary": "JNJ jumps over 6% on Q2 earnings beat and full-year guidance increase, driven by strong pharma sales and improved MedTech sales.",
    "url": "https://finnhub.io/api/news?id=c113eeba59047726891ebafe2e0c2fbd692e1e9a7c0afd2960e5f167c80b7e74",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753104960,
      "headline": "Should J&J Stock Be in Your Portfolio After Q2 Beat & Guidance Raise?",
      "id": 136025435,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "JNJ jumps over 6% on Q2 earnings beat and full-year guidance increase, driven by strong pharma sales and improved MedTech sales.",
      "url": "https://finnhub.io/api/news?id=c113eeba59047726891ebafe2e0c2fbd692e1e9a7c0afd2960e5f167c80b7e74"
    }
  },
  {
    "ts": null,
    "headline": "Ophthalmic Implants Market: Focused Insights (2025-2030) Featuring Alcon, Carl Zeiss, Bausch + Lomb, Johnson & Johnson and 20 Other Industry Leaders",
    "summary": "North America leads with over 34% market share, while APAC shows a robust growth of 9.03%. Major players like Alcon, Carl Zeiss, and Johnson & Johnson drive innovation in advanced ocular devices and eye health solutions. Ophthalmic Implants Market Ophthalmic Implants Market Dublin, July 21, 2025 (GLOBE NEWSWIRE) -- The \"Ophthalmic Implants Market - Focused Insights 2025-2030\" has been added to ResearchAndMarkets.com's offering.The Ophthalmic Implants Market was valued at USD 5.28 billion in 2024",
    "url": "https://finnhub.io/api/news?id=f9a6b16f458c29dd0999ea7d5ad176735765d2192a0241a29e9e34efd1d3113f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753103580,
      "headline": "Ophthalmic Implants Market: Focused Insights (2025-2030) Featuring Alcon, Carl Zeiss, Bausch + Lomb, Johnson & Johnson and 20 Other Industry Leaders",
      "id": 136025436,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "North America leads with over 34% market share, while APAC shows a robust growth of 9.03%. Major players like Alcon, Carl Zeiss, and Johnson & Johnson drive innovation in advanced ocular devices and eye health solutions. Ophthalmic Implants Market Ophthalmic Implants Market Dublin, July 21, 2025 (GLOBE NEWSWIRE) -- The \"Ophthalmic Implants Market - Focused Insights 2025-2030\" has been added to ResearchAndMarkets.com's offering.The Ophthalmic Implants Market was valued at USD 5.28 billion in 2024",
      "url": "https://finnhub.io/api/news?id=f9a6b16f458c29dd0999ea7d5ad176735765d2192a0241a29e9e34efd1d3113f"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson (JNJ): I Counted 15 Separate Surprises,” Says Jim Cramer",
    "summary": "We recently published 10 Stocks Jim Cramer Discussed As He Shared Key Insights From Morgan Stanley’s CEO. Johnson & Johnson (NYSE:JNJ) is one of the stocks Jim Cramer recently discussed. Johnson & Johnson (NYSE:JNJ)’s shares are up by 5% since its latest earnings report, which saw it post $23.7 billion in sales to beat analyst […]",
    "url": "https://finnhub.io/api/news?id=2d4c5a7aeedc0fc8a6622f7112e440fcf810d834ca76c584506a3959c45455bf",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753101540,
      "headline": "Johnson & Johnson (JNJ): I Counted 15 Separate Surprises,” Says Jim Cramer",
      "id": 136025437,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "We recently published 10 Stocks Jim Cramer Discussed As He Shared Key Insights From Morgan Stanley’s CEO. Johnson & Johnson (NYSE:JNJ) is one of the stocks Jim Cramer recently discussed. Johnson & Johnson (NYSE:JNJ)’s shares are up by 5% since its latest earnings report, which saw it post $23.7 billion in sales to beat analyst […]",
      "url": "https://finnhub.io/api/news?id=2d4c5a7aeedc0fc8a6622f7112e440fcf810d834ca76c584506a3959c45455bf"
    }
  },
  {
    "ts": null,
    "headline": "Dentsply Sirona Appoints Daniel Scavilla as Chief Executive Officer",
    "summary": "Provides Select Preliminary Second Quarter 2025 Results and Reaffirms 2025 OutlookCHARLOTTE, N.C., July 21, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or “the Company”) (Nasdaq: XRAY) today announced that Daniel Scavilla, an established business leader with more than three decades of experience in the medical technology and pharmaceutical industries and a current member of the Board of Directors of Dentsply Sirona (the “Board”), has been appointed President and Chief Execut",
    "url": "https://finnhub.io/api/news?id=84e8960e15f046b6f27b1bbca90c7d59b8a0f3819ddbd1a5f143344921ed7119",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753101000,
      "headline": "Dentsply Sirona Appoints Daniel Scavilla as Chief Executive Officer",
      "id": 136025438,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Provides Select Preliminary Second Quarter 2025 Results and Reaffirms 2025 OutlookCHARLOTTE, N.C., July 21, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or “the Company”) (Nasdaq: XRAY) today announced that Daniel Scavilla, an established business leader with more than three decades of experience in the medical technology and pharmaceutical industries and a current member of the Board of Directors of Dentsply Sirona (the “Board”), has been appointed President and Chief Execut",
      "url": "https://finnhub.io/api/news?id=84e8960e15f046b6f27b1bbca90c7d59b8a0f3819ddbd1a5f143344921ed7119"
    }
  },
  {
    "ts": null,
    "headline": "Protagonist Announces Submission of NDA for First Icotrokinra U.S. FDA Approval Aiming to Revolutionize Treatment Paradigm for Adults and Adolescents with Plaque Psoriasis",
    "summary": "Icotrokinra is a first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor Filing based on unprecedented data package that met all primary endpoints across four Phase 3 studies, including head-to-head superiority ...",
    "url": "https://finnhub.io/api/news?id=544cae40cd563393d8f9c48f592407873c980718004bde900553ffe0312a41f9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753099500,
      "headline": "Protagonist Announces Submission of NDA for First Icotrokinra U.S. FDA Approval Aiming to Revolutionize Treatment Paradigm for Adults and Adolescents with Plaque Psoriasis",
      "id": 136025439,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Icotrokinra is a first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor Filing based on unprecedented data package that met all primary endpoints across four Phase 3 studies, including head-to-head superiority ...",
      "url": "https://finnhub.io/api/news?id=544cae40cd563393d8f9c48f592407873c980718004bde900553ffe0312a41f9"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson seeks first icotrokinra U.S. FDA approval aiming to revolutionize treatment paradigm for adults and adolescents with plaque psoriasis",
    "summary": "Johnson & Johnson (NYSE: JNJ) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking the first approval of icotrokinra, a first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor for the treatment of adults and pediatric patients 12 years of age and older with moderate to severe plaque psoriasis (PsO). Icotrokinra is uniquely designed to block the IL-23 receptor, which underpins the inflammatory",
    "url": "https://finnhub.io/api/news?id=49faf7e5ed479743effe3e06513fe3994dc8be2b95f02853f8517cd22190ab1a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753099200,
      "headline": "Johnson & Johnson seeks first icotrokinra U.S. FDA approval aiming to revolutionize treatment paradigm for adults and adolescents with plaque psoriasis",
      "id": 136025440,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (NYSE: JNJ) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking the first approval of icotrokinra, a first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor for the treatment of adults and pediatric patients 12 years of age and older with moderate to severe plaque psoriasis (PsO). Icotrokinra is uniquely designed to block the IL-23 receptor, which underpins the inflammatory",
      "url": "https://finnhub.io/api/news?id=49faf7e5ed479743effe3e06513fe3994dc8be2b95f02853f8517cd22190ab1a"
    }
  },
  {
    "ts": null,
    "headline": "Oral Care Market Analysis Report 2025-2032 | Emergence of Electric Toothbrushes, Introduction of Skincare-Inspired Oral Care Products, and Integration of AI in Toothbrushes",
    "summary": "The global oral care market is set for robust growth, driven by rising awareness of oral hygiene, increased demand for dental aesthetics, and eco-friendly products. Key players like Colgate-Palmolive, GlaxoSmithKline, and Johnson & Johnson lead the market. Toothpastes dominate product segments, projected to hold a 36.7% share by 2025, with adults as the major consumer group. Supermarkets/hypermarkets represent the largest distribution channel. The Asia-Pacific region is poised for rapid expansio",
    "url": "https://finnhub.io/api/news?id=6cc0a4f38b6e9606101a8d1ee3a655fc74769533faf283a32cca7122b3b5fe89",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753096380,
      "headline": "Oral Care Market Analysis Report 2025-2032 | Emergence of Electric Toothbrushes, Introduction of Skincare-Inspired Oral Care Products, and Integration of AI in Toothbrushes",
      "id": 136024362,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "The global oral care market is set for robust growth, driven by rising awareness of oral hygiene, increased demand for dental aesthetics, and eco-friendly products. Key players like Colgate-Palmolive, GlaxoSmithKline, and Johnson & Johnson lead the market. Toothpastes dominate product segments, projected to hold a 36.7% share by 2025, with adults as the major consumer group. Supermarkets/hypermarkets represent the largest distribution channel. The Asia-Pacific region is poised for rapid expansio",
      "url": "https://finnhub.io/api/news?id=6cc0a4f38b6e9606101a8d1ee3a655fc74769533faf283a32cca7122b3b5fe89"
    }
  },
  {
    "ts": null,
    "headline": "Urinary Incontinence Devices Company Evaluation Report 2025 | Coloplast, B. Braun, and Johnson & Johnson Lead the Market with Innovation, Global Expansion, and Diversified Healthcare Portfolios",
    "summary": "The Urinary Incontinence Devices Companies Quadrant delivers an in-depth analysis of the global urinary incontinence market, highlighting key players, technological advancements, and emerging trends. Evaluating over 100 companies, the report identifies 14 leaders in the EVA Films sector. The market's expansion is driven by a spike in urinary incontinence cases, a growing elderly population, and technological leaps in healthcare solutions. However, social stigma and environmental issues may imped",
    "url": "https://finnhub.io/api/news?id=cbf55d6d8a54a628acd8aa526b4c5274bf8e6865dc1cf5c90f347c93689b6f5f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753085400,
      "headline": "Urinary Incontinence Devices Company Evaluation Report 2025 | Coloplast, B. Braun, and Johnson & Johnson Lead the Market with Innovation, Global Expansion, and Diversified Healthcare Portfolios",
      "id": 136023608,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "The Urinary Incontinence Devices Companies Quadrant delivers an in-depth analysis of the global urinary incontinence market, highlighting key players, technological advancements, and emerging trends. Evaluating over 100 companies, the report identifies 14 leaders in the EVA Films sector. The market's expansion is driven by a spike in urinary incontinence cases, a growing elderly population, and technological leaps in healthcare solutions. However, social stigma and environmental issues may imped",
      "url": "https://finnhub.io/api/news?id=cbf55d6d8a54a628acd8aa526b4c5274bf8e6865dc1cf5c90f347c93689b6f5f"
    }
  }
]